The full text of this article hosted at iucr.org is unavailable due to technical difficulties.

Research Article

Systematic review of incidence studies of Parkinson's disease

Dominique Twelves BSc

University of Edinburgh Medical School, Scotland, United Kingdom

Search for more papers by this author
Kate S.M. Perkins MCRP (UK)

Department of Neurology, Aberdeen Royal Infirmary, Scotland, United Kingdom

Search for more papers by this author
Carl Counsell MD

Corresponding Author

Department of Neurology, Aberdeen Royal Infirmary, Scotland, United Kingdom

Department of Medicine and Therapeutics, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB25 2ZD, United Kingdom
Search for more papers by this author
First published: 17 September 2002
Cited by: 213

Abstract

Incidence studies of Parkinson's disease (PD) are important for both health‐care planning and epidemiological research. This report reviews the methods and results of previous incidence studies of PD and makes recommendations for future studies. Original articles that described the incidence of PD were located using several strategies. The methods were summarised, and the results of studies with similar methodologies were compared on a standardised population. Twenty‐five incidence studies were included. Each used different methods to identify incident patients, although most screened both primary care and hospital records. Only eight studies were prospective, and only two of these had any follow‐up. The diagnostic criteria for PD varied (11 studies used two or more cardinal motor features, four used the UK Brain Bank criteria), as did the exclusion criteria and the definition of an incident case. In 16 studies, attempts were made to confirm the diagnosis by examination of patients by a specialist as part of the study. None of the studies used identical methods, but five were sufficiently similar to merit comparison. Four of these gave a similar incidence (16–19/100,000/year), but one from Italy had a much lower incidence (8.4/100,000), the reason for which was unclear. Five studies found significantly greater incidence in men. This review highlights the difficulties in performing good quality incidence studies of PD. Further incidence studies using standardised methods are required. A set of minimal scientific criteria has been devised to improve the quality and consistency of future studies.

Number of times cited according to CrossRef: 213

  • , Decreased Cerebrospinal Fluid Aβ42 in Patients with Idiopathic Parkinson’s Disease and White Matter Lesions, Journal of Parkinson's Disease, 10.3233/JPD-181486, (1-7), (2019).
  • , Exacerbation of sensorimotor dysfunction in mice deficient in Atp13a2 and overexpressing human wildtype alpha-synuclein, Behavioural Brain Research, 343, (41), (2018).
  • , Chaperone-mediated autophagy as a therapeutic target for Parkinson disease, Expert Opinion on Therapeutic Targets, 10.1080/14728222.2018.1517156, 22, 10, (823-832), (2018).
  • , Inflammation and fatigue in early, untreated Parkinson's Disease, Acta Neurologica Scandinavica, 138, 5, (394-399), (2018).
  • , Methamphetamine use and future risk for Parkinson’s disease: Evidence and clinical implications, Drug and Alcohol Dependence, 10.1016/j.drugalcdep.2018.02.032, 187, (134-140), (2018).
  • , Age-related selection bias in Parkinson's disease research: are we recruiting the right participants?, Parkinsonism & Related Disorders, 10.1016/j.parkreldis.2018.05.027, 55, (128-133), (2018).
  • , Behavioral tests predicting striatal dopamine level in a rat hemi-Parkinson's disease model, Neurochemistry International, 10.1016/j.neuint.2018.11.005, (2018).
  • , Automated Mechanical Peripheral Stimulation Improves Gait Parameters in Subjects With Parkinson Disease and Freezing of Gait, American Journal of Physical Medicine & Rehabilitation, 10.1097/PHM.0000000000000890, 97, 6, (383-389), (2018).
  • , Computational Studies Applied to Flavonoids against Alzheimer’s and Parkinson’s Diseases, Oxidative Medicine and Cellular Longevity, 10.1155/2018/7912765, 2018, (1-21), (2018).
  • , Foreword of Volume 1, Neuromodulation, 10.1016/B978-0-12-805353-9.06001-0, (xi-xxii), (2018).
  • , Foreword of Volume 3, Neuromodulation, 10.1016/B978-0-12-805353-9.06003-4, (xv-xxvi), (2018).
  • , Foreword of Volume 2, Neuromodulation, 10.1016/B978-0-12-805353-9.06002-2, (xv-xxvi), (2018).
  • , Repurposing sex steroids and related drugs as potential treatment for Parkinson's disease, Neuropharmacology, 10.1016/j.neuropharm.2018.04.005, (2018).
  • , Biomarkers in Neurodegenerative Diseases, Neurodegenerative Diseases, 10.1007/978-3-319-57193-5_20, (491-528), (2017).
  • , A Novel Approach in Combination of 3D Gait Analysis Data for Aiding Clinical Decision-Making in Patients with Parkinson’s Disease, Intelligent Computing Theories and Application, 10.1007/978-3-319-63312-1_44, (504-514), (2017).
  • , Dysphagia in Parkinson’s Disease, , 10.1007/174_2017_118, (2017).
  • , Workforce unavailability in Parkinson's disease, Acta Neurologica Scandinavica, 135, 3, (332-338), (2016).
  • , A comprehensive overview of the neuropsychiatry of Parkinson's disease: A review, Bulletin of the Menninger Clinic, 10.1521/bumc.2017.81.1.53, 81, 1, (53-105), (2017).
  • , Neurosurgery in Russian Federation, Voprosy neirokhirurgii imeni N.N. Burdenko, 10.17116/neiro20178075-12, 81, 1, (5), (2017).
  • , Reproductive factors and risk of Parkinson’s disease in women: A meta-analysis of observational studies, Behavioural Brain Research, 10.1016/j.bbr.2017.07.025, 335, (103-110), (2017).
  • , ACR–ACNM Practice Parameter for the Performance of Dopamine Transporter (DaT) Single Photon Emission Computed Tomography (SPECT) Imaging for Movement Disorders, Clinical Nuclear Medicine, 10.1097/RLU.0000000000001815, 42, 11, (847-852), (2017).
  • , Pesticides and Parkinson's Disease: Current Experimental and Epidemiological Evidence, Environmental Factors in Neurodegenerative Diseases, 10.1016/bs.ant.2017.07.004, (83-117), (2017).
  • , Autonomic History Taking and Key Symptoms: Where Is the Autonomic Disease?, Bedside Approach to Autonomic Disorders, 10.1007/978-3-319-05143-7_2, (15-36), (2017).
  • 2017 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) Kansas City, MO 2017 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) IEEE , (2017). 978-1-5090-3050-7 Multi-label learning by exploiting label correlations for TCM diagnosing Parkinson's disease , (2017). 590 594 8217717 , 10.1109/BIBM.2017.8217717 http://ieeexplore.ieee.org/document/8217717/
  • , Medication Therapy Management Service for Patients with Parkinson’s Disease: A Before-and-After Study, Neurology and Therapy, 10.1007/s40120-016-0046-4, 5, 1, (85-99), (2016).
  • , Targeting delivery in Parkinson's disease, Drug Discovery Today, 10.1016/j.drudis.2016.06.003, 21, 8, (1313-1320), (2016).
  • , Comparative epidemiology of incident Parkinson's disease in Cambridgeshire, UK: Table 1, Journal of Neurology, Neurosurgery & Psychiatry, 10.1136/jnnp-2015-312581, 87, 9, (1034-1036), (2016).
  • , Transforaminal Percutaneous Endoscopic Discectomy for Lumbar Disc Herniation in Parkinson's Disease: A Case-Control Study, Asian Spine Journal, 10.4184/asj.2016.10.4.671, 10, 4, (671), (2016).
  • , The social impact of Parkinson's disease in Spain: Report by the Spanish Foundation for the Brain, Neurología (English Edition), 10.1016/j.nrleng.2013.04.008, 31, 6, (401-413), (2016).
  • , Time trends in the prevalence and incidence of Parkinson's disease in Taiwan: A nationwide, population-based study, Journal of the Formosan Medical Association, 10.1016/j.jfma.2015.05.014, 115, 7, (531-538), (2016).
  • , Co-morbidity burden in Parkinson’s disease: Comparison with controls and its influence on prognosis, Parkinsonism & Related Disorders, 10.1016/j.parkreldis.2016.05.013, 28, (124-129), (2016).
  • , Role of Neuroinflammation in Parkinson Disease: The Enigma Continues, Mayo Clinic Proceedings, 10.1016/j.mayocp.2016.08.010, 91, 10, (1328-1330), (2016).
  • , Informe de la Fundación del Cerebro sobre el impacto social de la enfermedad de Parkinson en España, Neurología, 10.1016/j.nrl.2013.04.008, 31, 6, (401-413), (2016).
  • , The Implications of Parkinson's Disease for Women's Health, Journal of Obstetric, Gynecologic & Neonatal Nursing, 10.1016/j.jogn.2016.02.015, 45, 5, (723-736), (2016).
  • , Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis, Journal of Neurology, Neurosurgery & Psychiatry, 10.1136/jnnp-2015-312283, 87, 9, (952-957), (2015).
  • , Deep brain stimulation for Parkinson's disease: current status and future outlook, Neurodegenerative Disease Management, 10.2217/nmt-2016-0012, 6, 4, (299-317), (2016).
  • , Health Effects and Medicare Trajectories: Population-Based Analysis of Morbidity and Mortality Patterns, Biodemography of Aging, 10.1007/978-94-017-7587-8_3, (47-93), (2016).
  • , Epidemiology of alpha-synucleinopathies, Neuroepidemiology, 10.1016/B978-0-12-802973-2.00009-4, (153-158), (2016).
  • , Verbal memory declines more in female patients with Parkinson's disease: the importance of gender-corrected normative data, Psychological Medicine, 10.1017/S0033291716000908, 46, 11, (2275-2286), (2016).
  • , Pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson's disease: Systematic review and meta-analysis, Parkinsonism & Related Disorders, 10.1016/j.parkreldis.2016.03.002, 27, (25-34), (2016).
  • , Using Canadian Primary Care Sentinel Surveillance Network data to examine depression in patients with a diagnosis of Parkinson disease: a retrospective cohort study, CMAJ Open, 10.9778/cmajo.20160052, 4, 3, (E417-E423), (2016).
  • , Transforaminal Percutaneous Endoscopic Discectomy in Parkinson Disease: Preliminary Results and Short Review of the Literature, Korean Journal of Spine, 10.14245/kjs.2016.13.3.144, 13, 3, (144), (2016).
  • , Use of a driving simulator to improve on‐road driving performance and cognition in persons with Parkinson's disease: A pilot study, Australian Occupational Therapy Journal, 63, 6, (408-414), (2016).
  • , Quantitative expression proteomics and phosphoproteomics profile of brain from PINK1 knockout mice: insights into mechanisms of familial Parkinson's disease, Journal of Neurochemistry, 133, 5, (750-765), (2015).
  • , Navigational Memory Functional Magnetic Resonance Imaging: A Test for Concussion in Children, Journal of Neurotrauma, 10.1089/neu.2014.3470, 32, 10, (712-722), (2015).
  • , Épidémiologie, La maladie de Parkinson, 10.1016/B978-2-294-74232-3.00001-5, (1-5.e2), (2015).
  • , Does HIV Infection Alter Parkinson Disease?, JAIDS Journal of Acquired Immune Deficiency Syndromes, 10.1097/QAI.0000000000000677, 70, 2, (129-136), (2015).
  • 2015 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) Washington, DC, USA 2015 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) IEEE , (2015). 978-1-4673-6799-8 Entropy chain multi-label classifiers for traditional medicine diagnosing Parkinson's disease , (2015). 856 862 7359797 , 10.1109/BIBM.2015.7359797 http://ieeexplore.ieee.org/document/7359797/
  • , Parkinson’s Disease Prevalence and Proximity to Agricultural Cultivated Fields, Parkinson's Disease, 10.1155/2015/576564, 2015, (1-7), (2015).
  • , Mapping from the Parkinson’s Disease Questionnaire PDQ-39 to the Generic EuroQol EQ-5D-3L, Medical Decision Making, 10.1177/0272989X15584921, 35, 7, (902-911), (2015).
  • , Rab11 modulates α-synuclein-mediated defects in synaptic transmission and behaviour, Human Molecular Genetics, 10.1093/hmg/ddu521, 24, 4, (1077-1091), (2014).
  • , Quantitative motor assessment of dyskinesias in Parkinson’s disease, Journal of Neural Transmission, 10.1007/s00702-015-1383-7, 122, 9, (1271-1278), (2015).
  • , Characterizing gait asymmetry via frequency sub-band components of the ground reaction force, Biomedical Signal Processing and Control, 10.1016/j.bspc.2014.11.008, 18, (56-60), (2015).
  • , Combining cell transplants or gene therapy with deep brain stimulation for Parkinson's disease, Movement Disorders, 30, 2, (190-195), (2014).
  • , Cytoprotective effects of hydrogen sulfide-releasing N-methyl- d -aspartate receptor antagonists mediated by intracellular sulfane sulfur , Med. Chem. Commun., 10.1039/C4MD00180J, 5, 10, (1577-1583), (2014).
  • , Knowledge and Attitudes About Parkinson’s Disease Among a Diverse Group of Older Adults, Journal of Cross-Cultural Gerontology, 10.1007/s10823-014-9233-x, 29, 3, (339-352), (2014).
  • , Éducation thérapeutique chez le patient parkinsonien : le programme ETPARK, Revue Neurologique, 10.1016/j.neurol.2013.08.007, 170, 2, (128-133), (2014).
  • , Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial, The Lancet, 10.1016/S0140-6736(14)60683-8, 384, 9949, (1196-1205), (2014).
  • , Sex Differences in the Pharmacokinetics of Levodopa in Elderly Patients With Parkinson Disease, Clinical Neuropharmacology, 10.1097/WNF.0000000000000051, 37, 6, (173-176), (2014).
  • , Electrophysiological Evaluation of Oropharyngeal Dysphagia in Parkinson’s Disease, Journal of Movement Disorders, 10.14802/jmd.14008, 7, 2, (31-56), (2014).
  • , Long-Term Exposure to Paraquat Alters Behavioral Parameters and Dopamine Levels in Adult Zebrafish ( Danio Rerio ) , Zebrafish, 10.1089/zeb.2013.0923, 11, 2, (142-153), (2014).
  • , The prevalence and incidence of Parkinson’s disease in China: a systematic review and meta-analysis, Journal of Neural Transmission, 10.1007/s00702-013-1092-z, 121, 2, (123-134), (2013).
  • , The incidence of Parkinson's disease in the North-East of England, Age and Ageing, 10.1093/ageing/aft091, 43, 2, (257-263), (2013).
  • , Enhancing case ascertainment of Parkinson's disease using Medicare claims data in a population‐based cohort: the Cardiovascular Health Study, Pharmacoepidemiology and Drug Safety, 23, 2, (119-127), (2013).
  • , Parkinson's disease and risk of mortality: meta‐analysis and systematic review, Acta Neurologica Scandinavica, 129, 2, (71-79), (2013).
  • , The prevalence of Parkinson's disease: A systematic review and meta‐analysis, Movement Disorders, 29, 13, (1583-1590), (2014).
  • , Considerations on the role of environmental toxins in idiopathic Parkinson’s disease pathophysiology, Translational Neurodegeneration, 10.1186/2047-9158-3-10, 3, 1, (10), (2014).
  • , Age-, gender-, and socioeconomic status-specific incidence of Parkinson's disease and parkinsonism in North East Scotland: The PINE study, Parkinsonism & Related Disorders, 10.1016/j.parkreldis.2013.01.014, 19, 5, (515-521), (2013).
  • , A cohort study on diet and the risk of Parkinson's disease: the role of food groups and diet quality, British Journal of Nutrition, 10.1017/S0007114512000955, 109, 02, (329-337), (2012).
  • , Oxidative damage to macromolecules in human Parkinson disease and the rotenone model, Free Radical Biology and Medicine, 10.1016/j.freeradbiomed.2013.01.003, 62, (111-120), (2013).
  • , Use of the Gait Deviation Index and spatiotemporal variables for the assessment of dual task interference paradigm, Journal of Bodywork and Movement Therapies, 10.1016/j.jbmt.2012.03.001, 17, 1, (19-27), (2013).
  • , Biomaterial approaches to gene therapies for neurodegenerative disorders of the CNS, Biomaterials Science, 10.1039/c3bm60030k, 1, 6, (556), (2013).
  • , Targeting the Chameleon: a Focused Look at α-Synuclein and Its Roles in Neurodegeneration, Molecular Neurobiology, 10.1007/s12035-012-8334-1, 47, 2, (446-459), (2012).
  • , Time trends in incidence of Parkinson’s disease diagnosis in UK primary care, Journal of Neurology, 10.1007/s00415-012-6804-z, 260, 5, (1351-1357), (2012).
  • , Emerging drugs for autonomic dysfunction in Parkinson's disease, Expert Opinion on Emerging Drugs, 10.1517/14728214.2013.766168, 18, 1, (39-53), (2013).
  • , Changes in Clinical Management and Diagnosis following DaTscan™ SPECT Imaging in Patients with Clinically Uncertain Parkinsonian Syndromes: A 12-Week Follow-Up Study, Neurodegenerative Diseases, 10.1159/000337351, 11, 1, (22-32), (2013).
  • , A team approach to the complexities of Parkinson's, British Journal of Healthcare Assistants, 7, 11, (533), (2013).
  • , Rotigotine transdermal patch for the treatment of Parkinson’s Disease, Fundamental & Clinical Pharmacology, 27, 1, (81-95), (2012).
  • , Neurosteroid and neurotransmitter alterations in Parkinson’s disease, Frontiers in Neuroendocrinology, 10.1016/j.yfrne.2013.03.001, 34, 2, (132-142), (2013).
  • , Glycogen Synthase Kinase-3 Inhibitors as Potent Therapeutic Agents for the Treatment of Parkinson Disease., ACS Chemical Neuroscience, 10.1021/cn300182g, 4, 2, (350-360), (2013).
  • , Management of patients with Parkinson disease, The Nurse Practitioner, 10.1097/01.NPR.0000434090.96229.5c, 38, 10, (34-43), (2013).
  • , Association of nicotine dependence susceptibility gene, CHRNA5, with Parkinson's disease age at onset: Gene and smoking status interaction, Parkinsonism & Related Disorders, 10.1016/j.parkreldis.2012.07.007, 19, 1, (72-76), (2013).
  • , Symptom prevalence, severity and palliative care needs assessment using the Palliative Outcome Scale: A cross-sectional study of patients with Parkinson’s disease and related neurological conditions, Palliative Medicine, 10.1177/0269216312465783, 27, 8, (722-731), (2012).
  • , Reproductive factors and clinical features of Parkinson's disease, Parkinsonism & Related Disorders, 10.1016/j.parkreldis.2013.07.020, 19, 12, (1094-1099), (2013).
  • , A review of cognitive and other non-motor problems in Parkinson’s disease, Aging Health, 10.2217/ahe.12.84, 9, 1, (89-102), (2013).
  • , Cost‐effectiveness of deep brain stimulation in patients with Parkinson's disease, Movement Disorders, 28, 6, (763-771), (2013).
  • , Timing of deep brain stimulation in Parkinson disease: A need for reappraisal?, Annals of Neurology, 73, 5, (565-575), (2013).
  • , Exposure to estrogen and women's risk for Parkinson's disease: A prospective cohort study in Denmark, Parkinsonism & Related Disorders, 10.1016/j.parkreldis.2013.01.008, 19, 4, (457-460), (2013).
  • , A systematic review of biomarkers for disease progression in Parkinson’s disease, BMC Neurology, 10.1186/1471-2377-13-35, 13, 1, (2013).
  • , Incidence and prevalence of Parkinson’s disease in Buenos Aires City, Argentina, European Journal of Neurology, 19, 8, (1108-1113), (2012).
  • , Pramipexole use and the risk of pneumonia, BMC Neurology, 10.1186/1471-2377-12-113, 12, 1, (2012).
  • , Effets chroniques des pesticides sur le système nerveux central : état des connaissances épidémiologiques, Revue d'Épidémiologie et de Santé Publique, 10.1016/j.respe.2012.03.006, 60, 5, (389-400), (2012).
  • , Incidence and mortality of Parkinson’s disease in older Canadians, Parkinsonism & Related Disorders, 10.1016/j.parkreldis.2011.11.018, 18, 4, (327-331), (2012).
  • , Physical Activity across Frailty Phenotypes in Females with Parkinson’s Disease, Journal of Aging Research, 10.1155/2012/468156, 2012, (1-8), (2012).
  • , A case control study of women with Parkinson's disease and their fertility characteristics, Journal of the Neurological Sciences, 10.1016/j.jns.2012.05.026, 319, 1-2, (135-138), (2012).
  • , Signaling pathways mediating the neuroprotective effects of sex steroids and SERMs in Parkinson’s disease, Frontiers in Neuroendocrinology, 10.1016/j.yfrne.2012.02.003, 33, 2, (169-178), (2012).
  • , Gene Therapy for Parkinson's Disease, Parkinson's Disease, 10.1155/2012/757305, 2012, (1-13), (2012).
  • , Neurological disorder screening in the elderly in low-income countries, Journal of Neurology, 10.1007/s00415-012-6482-x, 259, 10, (2189-2197), (2012).
  • , Effects of music therapy on facial expression of individuals with Parkinson’s disease: A pilot study, Musicae Scientiae, 10.1177/1029864912458917, 16, 3, (392-400), (2012).
  • , Evaluating Changes in the Prevalence of the Autism Spectrum Disorders (ASDs), Public Health Reviews, 10.1007/BF03391685, 34, 2, (2012).
  • , Parkinson's disease – pathology, aetiology and diagnosis, Reviews in Clinical Gerontology, 10.1017/S095925981200007X, 22, 03, (165-178), (2012).
  • , Presynaptic dysfunction in Parkinson's disease: a focus on LRRK2, Biochemical Society Transactions, 10.1042/BST20120124, 40, 5, (1111-1116), (2012).
  • , Emerging analgesic drugs for Parkinson's disease, Expert Opinion on Emerging Drugs, 10.1517/14728214.2012.677949, 17, 2, (157-171), (2012).
  • , Dopamine agonist use and the risk of heart failure, Pharmacoepidemiology and Drug Safety, 21, 1, (34-41), (2011).
  • , Nutraceuticals and their preventive or potential therapeutic value in Parkinson's disease, Nutrition Reviews, 70, 7, (373-386), (2012).
  • , Association of Parkinson's disease with infections and occupational exposure to possible vectors, Movement Disorders, 27, 9, (1111-1117), (2012).
  • , Validity and reliability of the Geriatric Anxiety Inventory in Parkinson's disease*, Australasian Journal on Ageing, 31, 1, (13-16), (2010).
  • , Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs, Drug and Alcohol Dependence, 10.1016/j.drugalcdep.2011.06.013, 120, 1-3, (35-40), (2012).
  • , The genetics of sex differences in brain and behavior, Frontiers in Neuroendocrinology, 10.1016/j.yfrne.2010.10.001, 32, 2, (227-246), (2011).
  • , Factors associated with depression in Parkinson's disease, Journal of Affective Disorders, 10.1016/j.jad.2011.01.021, 132, 1-2, (82-88), (2011).
  • , Modelling the Cost Effectiveness of Treatments for Parkinsonʼs Disease, PharmacoEconomics, 10.2165/11587110-000000000-00000, 29, 12, (1025-1049), (2011).
  • , Epidemiology and etiology of Parkinson’s disease: a review of the evidence, European Journal of Epidemiology, 10.1007/s10654-011-9581-6, 26, S1, (1-58), (2011).
  • , Pramipexole for the treatment of early Parkinson’s disease, Expert Review of Neurotherapeutics, 10.1586/ern.11.75, 11, 7, (925-935), (2014).
  • 2011 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society Boston, MA 2011 Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE , (2011). 978-1-4577-1589-1 978-1-4244-4121-1 978-1-4244-4122-8 Atlas-based segmentation for globus pallidus internus targeting on low-resolution MRI , (2011). 5706 5709 6091381 , 10.1109/IEMBS.2011.6091381 http://ieeexplore.ieee.org/document/6091381/
  • , Parkinson’s Disease and Dementia: A Longitudinal Study (DEMPARK), Neuroepidemiology, 10.1159/000331490, 37, 3-4, (168-176), (2011).
  • , Factors related to functional independence in females with Parkinson's disease: A systematic review, Maturitas, 10.1016/j.maturitas.2011.05.009, 69, 4, (304-311), (2011).
  • , Prevalence of depression in Parkinson's disease: Effects of disease stage, motor subtype and gender, Journal of the Neurological Sciences, 10.1016/j.jns.2011.07.007, 310, 1-2, (220-224), (2011).
  • , Nanocomposites for Neurodegenerative Diseases: Hydrogel-Nanoparticle Combinations for a Challenging Drug Delivery, The International Journal of Artificial Organs, 34, 12, (1115), (2011).
  • , Assessment methods and factors associated with depression in Parkinson's disease, Journal of the Neurological Sciences, 10.1016/j.jns.2011.06.031, 310, 1-2, (208-210), (2011).
  • , Elevated Levels of α-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naïve Patients with Parkinson's Disease, Journal of Clinical Neurology, 10.3988/jcn.2011.7.4.215, 7, 4, (215), (2011).
  • , Safety of rasagiline for the treatment of Parkinson's disease, Expert Opinion on Drug Safety, 10.1517/14740338.2011.573784, 10, 4, (633-643), (2011).
  • , Inhaled Hydrogen Sulfide Prevents Neurodegeneration and Movement Disorder in a Mouse Model of Parkinson's Disease, Antioxidants & Redox Signaling, 10.1089/ars.2010.3671, 15, 2, (343-352), (2011).
  • , Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Combined with Magnetic Beads for Detecting Serum Protein Biomarkers in Parkinson’s Disease, European Neurology, 10.1159/000323427, 65, 2, (105-111), (2011).
  • , Parkinson’s disease risk from ambient exposure to pesticides, European Journal of Epidemiology, 10.1007/s10654-011-9574-5, 26, 7, (547-555), (2011).
  • , Épidémiologie, La maladie de Parkinson, 10.1016/B978-2-294-71153-4.00001-9, (1-8), (2011).
  • , Human ES and iPS cells as cell sources for the treatment of Parkinson's disease: Current state and problems, Journal of Cellular Biochemistry, 109, 2, (292-301), (2009).
  • , Maladie de Parkinson : une maladie à forte composante environnementale ?, Revue Neurologique, 10.1016/j.neurol.2010.07.008, 166, 10, (757-763), (2010).
  • , Deep brain stimulation for movement disorders, Neurobiology of Disease, 10.1016/j.nbd.2009.11.019, 38, 3, (338-345), (2010).
  • , Piloting the NPF data-driven quality improvement initiative, Parkinsonism & Related Disorders, 10.1016/j.parkreldis.2010.06.005, 16, 8, (517-521), (2010).
  • , Expression of insulin-like growth factor-1 and insulin-like growth factor binding proteins in the serum and cerebrospinal fluid of patients with Parkinson’s disease, Journal of Clinical Neuroscience, 10.1016/j.jocn.2009.08.013, 17, 5, (623-627), (2010).
  • , Parkinson Disease and Exercise, Comprehensive Physiology, (833-848), (2013).
  • , Genetics and Genomics of Parkinson's Disease, Essentials of Genomic and Personalized Medicine, 10.1016/B978-0-12-374934-5.00054-4, (700-711), (2010).
  • , Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease, Expert Opinion on Pharmacotherapy, 10.1517/14656566.2010.510515, 11, 13, (2221-2230), (2010).
  • , Parkinson’s Disease, the Inflammatory Pathway and Anti-Inflammatory Drugs: An Overview, Journal of Medical Sciences(Faisalabad), 10.3923/jms.2010.49.58, 10, 3, (49-58), (2010).
  • , Parkinsonism and Other Movement Disorders, Brocklehurst's Textbook of Geriatric Medicine and Gerontology, 10.1016/B978-1-4160-6231-8.10064-9, (511-519), (2010).
  • , Expression of hepatocyte growth factor in the serum and cerebrospinal fluid of patients with Parkinson’s disease, Journal of Clinical Neuroscience, 10.1016/j.jocn.2010.04.034, 17, 12, (1553-1556), (2010).
  • , Incidence of Parkinson's disease and parkinsonism in northern Sweden: A population‐based study, Movement Disorders, 25, 3, (341-348), (2010).
  • , Incidence of Parkinson's disease and atypical parkinsonism: Russian population‐based study, Movement Disorders, 25, 3, (349-356), (2010).
  • , Reduced 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy)-Initiated Oxidative DNA Damage and Neurodegeneration in Prostaglandin H Synthase-1 Knockout Mice, ACS Chemical Neuroscience, 10.1021/cn900022w, 1, 5, (366-380), (2010).
  • , Gait Training With Progressive External Auditory Cueing in Persons With Parkinson's Disease, Archives of Physical Medicine and Rehabilitation, 10.1016/j.apmr.2010.04.012, 91, 8, (1255-1261), (2010).
  • , A clinic‐based screening of mutations in exons 31, 34, 35, 41, and 48 of LRRK2 in Iranian Parkinson's disease patients, Movement Disorders, 24, 7, (1023-1027), (2009).
  • , Parkinson's Disease: Genomic Perspectives, Genomic and Personalized Medicine, 10.1016/B978-0-12-369420-1.00100-1, (1233-1242), (2009).
  • , Autonomic Dysfunctions in Parkinsonian Disorders, Journal of Movement Disorders, 10.14802/jmd.09019, 2, 2, (72-77), (2009).
  • , Changes in Walking Activity and Endurance Following Rehabilitation for People With Parkinson Disease, Archives of Physical Medicine and Rehabilitation, 10.1016/j.apmr.2008.06.034, 90, 1, (43-50), (2009).
  • , Novel investigational adenosine A 2A receptor antagonists for Parkinson's disease , Expert Opinion on Investigational Drugs, 10.1517/13543780903241615, 18, 11, (1619-1631), (2009).
  • , Delayed and lasting effects of deep brain stimulation on locomotion in Parkinson's disease, Chaos: An Interdisciplinary Journal of Nonlinear Science, 10.1063/1.3127585, 19, 2, (026114), (2009).
  • , Parkinson's disease, The Lancet, 10.1016/S0140-6736(09)60492-X, 373, 9680, (2055-2066), (2009).
  • , Trends in Parkinson’s disease related mortality in England and Wales, 1993–2006, European Journal of Neurology, 16, 9, (1010-1016), (2009).
  • , Serotonin and dopamine transporter genes do not influence depression in Parkinson's disease, Movement Disorders, 24, 1, (111-115), (2009).
  • , Parkinson’s Disease: An Overview of Pathogenesis, Oxidative Neural Injury, 10.1007/978-1-60327-342-8_10, (159-178), (2009).
  • , Systematic Review of the Prevalence and Incidence of Parkinson’s Disease in Asia, Journal of Epidemiology, 10.2188/jea.JE20081034, 19, 6, (281-293), (2009).
  • , The treatment of movement disorders by deep brain stimulation, Neurotherapeutics, 10.1016/j.nurt.2007.10.072, 5, 1, (26-36), (2008).
  • , An analysis of genetic studies of Parkinson's disease in Africa, Parkinsonism & Related Disorders, 10.1016/j.parkreldis.2007.08.006, 14, 3, (177-182), (2008).
  • , Disease-modifying drugs and Parkinson's disease, Progress in Neurobiology, 10.1016/j.pneurobio.2007.10.003, 84, 1, (25-39), (2008).
  • , Geographical variation of medicated parkinsonism in Finland during 1995 to 2000, Movement Disorders, 23, 7, (1024-1031), (2008).
  • , AGE BIAS IN CLINICAL TRIALS OF PARKINSON'S DISEASE TREATMENT, Journal of the American Geriatrics Society, 56, 12, (2353-2354), (2008).
  • , Epidemiology of Parkinson’s disease, Journal of Neurology, 10.1007/s00415-008-5004-3, 255, S5, (18-32), (2008).
  • , The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I, Journal of Neuropathology & Experimental Neurology, 10.1097/nen.0b013e3180415e42, 66, 4, (251-257), (2007).
  • , Epidemiologic studies of environmental exposures in Parkinson's disease, Journal of the Neurological Sciences, 10.1016/j.jns.2007.06.024, 262, 1-2, (37-44), (2007).
  • , Epidemiology of Parkinson's disease, Parkinson's Disease and Related Disorders, Part I, 10.1016/S0072-9752(07)83006-5, (129-151), (2007).
  • , Incidence of Parkinson's disease in Singapore, Parkinsonism & Related Disorders, 10.1016/j.parkreldis.2006.07.003, 13, 1, (40-43), (2007).
  • , Interaction between genes and environment in neurodegenerative diseases, Comptes Rendus Biologies, 10.1016/j.crvi.2007.02.018, 330, 4, (318-328), (2007).
  • , Molecular pathways and genetic aspects of Parkinson’s disease: from bench to bedside, Expert Review of Neurotherapeutics, 10.1586/14737175.7.12.1693, 7, 12, (1693-1729), (2014).
  • , Mitochondrial Disease—Its Impact, Etiology, and Pathology, The Mitochondrion in the Germline and Early Development, 10.1016/S0070-2153(06)77005-3, (113-155), (2007).
  • , Predicting the cost of Parkinson's disease, Movement Disorders, 22, 6, (804-812), (2007).
  • , Unresolved issues relating to the Shaking Palsy on the celebration of James Parkinson's 250th birthday, Movement Disorders, 22, S17, (S327-S334), (2007).
  • , Validity of Hamilton depression inventory in Parkinson's disease, Movement Disorders, 22, 3, (399-403), (2007).
  • , KDI tripeptide of γ1 laminin protects rat dopaminergic neurons from 6‐OHDA induced toxicity, Journal of Neuroscience Research, 84, 3, (655-665), (2006).
  • , The frequency and validity of self-reported diagnosis of Parkinson's Disease in the UK elderly: MRC CFAS cohort, BMC Neurology, 10.1186/1471-2377-6-29, 6, 1, (2006).
  • , LRRK2: a common pathway for parkinsonism, pathogenesis and prevention?, Trends in Molecular Medicine, 10.1016/j.molmed.2005.12.004, 12, 2, (76-82), (2006).
  • , Parkinson's Disease, Wiley Handbook of Current and Emerging Drug Therapies, (2006).
  • , Screening for undiagnosed parkinsonism in people aged 65 years and over in the community, Parkinsonism & Related Disorders, 10.1016/j.parkreldis.2005.08.005, 12, 2, (79-85), (2006).
  • , Neural stimulation for Parkinson’s disease: current therapies and future directions, Expert Review of Neurotherapeutics, 10.1586/14737175.6.1.101, 6, 1, (101-109), (2014).
  • , Pilot study of the incidence and prognosis of degenerative Parkinsonian disorders in Aberdeen, United Kingdom: Methods and preliminary results, Movement Disorders, 21, 7, (976-982), (2006).
  • , The neglected burden of stroke in Sub‐Saharan Africa, International Journal of Stroke, 1, 4, (180-190), (2006).
  • , Use of antiparkinsonian drugs in Denmark: Results from a nationwide pharmacoepidemiological study, Movement Disorders, 21, 8, (1221-1225), (2006).
  • , Parkinson’s disease: a rethink of rodent models, Experimental Brain Research, 10.1007/s00221-006-0461-3, 173, 2, (196-204), (2006).
  • , Parkinson??s Disease and Genetics, The Neurologist, 10.1097/01.nrl.0000237141.29970.e3, 12, 5, (240-244), (2006).
  • , Schlaf bei neurodegenerativen ErkrankungenSleep in neurodegenerative disorders, Der Nervenarzt, 10.1007/s00115-006-2151-6, 77, 10, (1251-1260), (2006).
  • , The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy, British Journal of Pharmacology, 146, 8, (1041-1059), (2009).
  • , Cost of Parkinson's disease in Europe, European Journal of Neurology, 12, (68-73), (2005).
  • , Pesticides and Parkinson’s Disease—Is There a Link?, Environmental Health Perspectives, 10.1289/ehp.8095, 114, 2, (156-164), (2005).
  • , Prevalence and incidence of Parkinson's disease in Europe, European Neuropsychopharmacology, 10.1016/j.euroneuro.2005.04.007, 15, 4, (473-490), (2005).
  • , Age-dependent dopaminergic dysfunction in Nurr1 knockout mice, Experimental Neurology, 10.1016/j.expneurol.2004.08.035, 191, 1, (154-162), (2005).
  • , Genetic testing in Parkinson's disease, Movement Disorders, 20, 1, (1-10), (2004).
  • , Burden of disease related to Parkinson's disease in Spain in the year 2000, Movement Disorders, 20, 11, (1481-1487), (2005).
  • , Causes and consequences of Parkinson's disease, Nursing and Residential Care, 7, 4, (158), (2005).
  • , Early Environmental Origins of Neurodegenerative Disease in Later Life, Environmental Health Perspectives, 10.1289/ehp.7571, 113, 9, (1230-1233), (2005).
  • , Manganese‐Induced Parkinsonism and Parkinson's Disease, Annals of the New York Academy of Sciences, 1012, 1, (209-223), (2006).
  • , Neurodegeneration and neuroprotection in Parkinson disease, NeuroRX, 10.1602/neurorx.1.1.139, 1, 1, (139-154), (2004).
  • , Heart failure in Parkinson's disease: analysis of the United States medicare current beneficiary survey, Parkinsonism & Related Disorders, 10.1016/j.parkreldis.2004.04.001, 10, 7, (417-420), (2004).
  • , Systematic Assessment of Decision Models in Parkinson's Disease, Value in Health, 7, 5, (610-626), (2004).
  • , Regional cerebral blood flow in Parkinson's disease with and without dementia, NeuroImage, 10.1016/S1053-8119(03)00364-1, 20, 2, (1309-1319), (2003).
  • , Coenzyme Q10 for Parkinson's disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD008150.pub3, (2012).
  • , Piribedil for levodopa-induced complications in Parkinson's disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006707, (2007).
  • , Coenzyme Q10 for Parkinson's disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD008150.pub2, (2011).
  • , Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson’s Disease: A Network Meta-Analysis, Scientific Reports, 10.1038/srep45865, 8, (45865), (2017).
  • , Increase of Reproductive Life Span Delays Age of Onset of Parkinson’s Disease, Frontiers in Neurology, 10.3389/fneur.2017.00397, 8, (2017).
  • , Therapeutic interventions for daytime somnolence in Parkinson's disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006808, (2007).
  • , Parkin (PARK 2) Mutations Are Rare in Czech Patients with Early-Onset Parkinson's Disease, PLoS ONE, 10.1371/journal.pone.0107585, 9, 9, (e107585), (2014).
  • , Riluzole for Parkinson's disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD011303, (2014).
  • , Therapeutic interventions for sleep disorders in Parkinson's disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006809, (2007).
  • , Parkinson disease, Nature Reviews Disease Primers, 10.1038/nrdp.2017.13, 3, (17013), (2017).
  • , Piribedil versus levodopa in early Parkinson's disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006710, (2007).
  • , Monoamine oxidase B inhibitors for early Parkinson's disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD004898, (2004).
  • , Rethinking energy in parkinsonian motor symptoms: a potential role for neural metabolic deficits, Frontiers in Systems Neuroscience, 10.3389/fnsys.2014.00242, 8, (2015).
  • , Rasagiline for levodopa-induced motor complications in Parkinson´s disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006397, (2007).
  • , A Mobile Cloud-Based Parkinson’s Disease Assessment System for Home-Based Monitoring, JMIR mHealth and uHealth, 10.2196/mhealth.3956, 3, 1, (e29), (2015).
  • , Sulfotransferase 1A3/4 copy number variation is associated with neurodegenerative disease, The Pharmacogenomics Journal, 10.1038/tpj.2017.4, (2017).
  • , Analyzing the effectiveness of vocal features in early telediagnosis of Parkinson's disease, PLOS ONE, 10.1371/journal.pone.0182428, 12, 8, (e0182428), (2017).
  • , Piribedil for symptomatic management of Parkinson's disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006708, (2007).
  • , Monoamine oxidase B inhibitors for early Parkinson's disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD004898.pub2, (2005).
  • , Redox Mechanisms in Neurodegeneration: From Disease Outcomes to Therapeutic Opportunities, Antioxidants & Redox Signaling, 10.1089/ars.2017.7321, (2018).